Collaboration Period. The obligations of the Parties and the terms and conditions of this Article II shall expire on the third (3rd) anniversary of the Effective Date (the “Collaboration Period”), unless earlier terminated in accordance with the provisions of this Agreement or extended pursuant to the following sentence. Novartis may, in its sole discretion, extend the Collaboration Period for two (2) additional one-year periods.
Collaboration Period. (TIME) means time for which unit members are to use for preparation with additional unit members in their grade level, subject area, or cross-curriculum areas.
Collaboration Period. 3.1.1 The definition of “Collaboration Period” set forth in Section 1.1.30 of the License Agreement is hereby deleted and replaced with: “‘Collaboration Period’ means the date beginning on the Effective Date and ending, subject to the proviso below, [**] after the completion of [**] the Phase I/II Clinical Trial, provided, however, that in the event Pfizer determines and notifies Spark, in writing, that clinical comparability (as compared to patients dosed with Licensed Product containing Compound produced using the “Process 1” manufacturing process) is demonstrated [**] treated with Licensed Product containing Compound produced using the “Process 2” manufacturing process (based on the clinical comparability criteria set forth in Exhibit B attached to the Second Amendment of this License Agreement), the Collaboration Period will end upon the later of (i) such determination and notification if the [**], in which event the [**] or (ii) if the [**] prior to such determination and notification, the date that is [**]. For the avoidance of doubt, the Collaboration Period shall end automatically as set forth above in this Section 1.1.30 and, except as expressly provided above in this Section 1.1.30, shall not require Pfizer’s determination of clinical comparability.”
3.1.2 Both during and following the Collaboration Period, each Party shall conduct the activities assigned to it as and when provided under the Roles and Responsibilities Plan attached to this Second Amendment as Exhibit C (the “Roles and Responsibilities Plan”). Without limiting the generality of the foregoing, Spark shall use Commercially Reasonable Efforts (a) to conduct and complete [**] the Phase I/II Clinical Trial, [**], as soon as practicable CONFIDENTIAL EXECUTION VERSIONNovember 6, 2017 after the Second Amendment Effective Date, with the goal of completing the same by [**], and (b) if Pfizer has not concluded that the [**] or if Pfizer otherwise requests Spark to [**] in the Phase I/II Clinical Trial, [**], as soon as practicable after the Second Amendment Effective Date, with the goal of completing the same by [**]. Notwithstanding any provision in the License Agreement or this Second Amendment to the contrary, (i) the INDs for the Spark Phase I/II Clinical Trials shall not be transferred to Pfizer until each of the items in the Roles and Responsibilities Plan that are identified as being required prior to the transfer to Pfizer of the INDs have been completed and (ii) Spark shall remain r...
Collaboration Period. Commencing on the Effective Date of this Amendment and continuing to December 31, 2012 date (the “Collaboration Period”), CCPR will operate the business of CompCare de Puerto Rico, Inc. as it pertains to MSO’s business and the Agreement as follows:
a. Subject to the terms of this Agreement and MSO’s rights as set forth below, CCPR will continue to be responsible for the MHSA Services as defined in the Agreement for:
i. professional services;
ii. institutional services; and
iii. pharmacy expenses, provided that CCPR’s responsibility for drugs shall be limited to drugs prescribed for mental health conditions as described in Exhibit B of the Agreement. Psychotropic drugs shall only be included as part of CCPR’s responsibility under Exhibit B if it is prescribed to address a current behavioral health diagnosis.
iv. The parties to this Amendment agree to settle a claim presented by CCPR on letter dated April 16, 2012, related to drugs not prescribed for mental health conditions. Notwithstanding the provision of Exhibit A with regard to a limitation of 45 days for claiming any amounts in the Pharmacy Adjustment, MSO and CCPR agree that all Pharmacy Adjustments previously identified, as it relates to drugs which have not been prescribed for mental health conditions, shall be settled for all periods prior to April 1, 2012 for an amount equal to $2.2 million, which sum was, prior to the date hereof, paid by MSO to providers for CCPR’s account. CCPR waives any additional claim related to its April 16, 2012 letter regarding drugs which have not been prescribed for mental health conditions for the period prior to April 1, 2012.
Collaboration Period. The Collaboration Period shall begin on the Effective Date and shall continue until the earlier of (i) the date two (2) years from the Effective date and (ii) the date of First Commercial Sale of the System, (the “Collaboration Period”), unless sooner terminated in accordance with this Section 8.
Collaboration Period. The term of the Collaboration shall commence on the Effective Date and, unless terminated earlier under ARTICLE 12, shall expire upon the completion of all development activities under the Development Plan (the “Collaboration Period”).
